Icosavax, Inc. Stock News

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st

Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 18.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines agains

- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage -

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. Vinco Ventures, Inc. (NASDAQ: BBIG) gained 58.8% to settle a

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs -

SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines agai

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phas

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offerin